MX2020010667A - Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos. - Google Patents

Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos.

Info

Publication number
MX2020010667A
MX2020010667A MX2020010667A MX2020010667A MX2020010667A MX 2020010667 A MX2020010667 A MX 2020010667A MX 2020010667 A MX2020010667 A MX 2020010667A MX 2020010667 A MX2020010667 A MX 2020010667A MX 2020010667 A MX2020010667 A MX 2020010667A
Authority
MX
Mexico
Prior art keywords
imbalanced
prodrugs
nucleotides
treatment
deoxynucleoside
Prior art date
Application number
MX2020010667A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Dipietro
Original Assignee
Modis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modis Therapeutics Inc filed Critical Modis Therapeutics Inc
Publication of MX2020010667A publication Critical patent/MX2020010667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020010667A 2018-04-12 2019-04-12 Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos. MX2020010667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656861P 2018-04-12 2018-04-12
PCT/US2019/027364 WO2019200340A1 (en) 2018-04-12 2019-04-12 Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools

Publications (1)

Publication Number Publication Date
MX2020010667A true MX2020010667A (es) 2021-01-08

Family

ID=68163825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010667A MX2020010667A (es) 2018-04-12 2019-04-12 Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos.

Country Status (10)

Country Link
US (2) US11628182B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773603A4 (cg-RX-API-DMAC7.html)
JP (2) JP7620781B2 (cg-RX-API-DMAC7.html)
CN (1) CN112384228A (cg-RX-API-DMAC7.html)
AU (2) AU2019253023B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020020804A2 (cg-RX-API-DMAC7.html)
CA (1) CA3096264A1 (cg-RX-API-DMAC7.html)
IL (1) IL277725B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020010667A (cg-RX-API-DMAC7.html)
WO (1) WO2019200340A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277725B2 (en) 2018-04-12 2024-02-01 Modis Therapeutics Inc Pro-drugs of deoxynucleosides for the treatment of diseases resulting from an imbalance in the nucleotide reserves
WO2022204555A1 (en) * 2021-03-26 2022-09-29 Zogenix Mds, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof
US20230000890A1 (en) * 2021-06-18 2023-01-05 Zogenix Mds, Inc. Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
EP0753525A4 (en) 1994-03-31 1997-09-03 Nippon Shinyaku Co Ltd CYCLIC NUCLEOTIDE DERIVATIVES
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
US10292996B2 (en) * 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
WO2016205671A1 (en) 2015-06-17 2016-12-22 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
EP3377512A4 (en) * 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. Nucleic Acid PRODRUGS
US11364257B2 (en) 2016-06-24 2022-06-21 Emory University Phosphoramidates for the treatment of hepatitis B virus
IL277725B2 (en) 2018-04-12 2024-02-01 Modis Therapeutics Inc Pro-drugs of deoxynucleosides for the treatment of diseases resulting from an imbalance in the nucleotide reserves

Also Published As

Publication number Publication date
US12419901B2 (en) 2025-09-23
JP7620781B2 (ja) 2025-01-24
JP7784411B2 (ja) 2025-12-11
AU2025201857A1 (en) 2025-04-03
WO2019200340A1 (en) 2019-10-17
AU2019253023B2 (en) 2025-01-23
AU2019253023A1 (en) 2020-11-12
US20230181617A1 (en) 2023-06-15
EP3773603A1 (en) 2021-02-17
CA3096264A1 (en) 2019-10-17
JP2024038011A (ja) 2024-03-19
US20230181616A1 (en) 2023-06-15
US20210077519A1 (en) 2021-03-18
JP2021521210A (ja) 2021-08-26
US11628182B2 (en) 2023-04-18
CN112384228A (zh) 2021-02-19
IL277725A (en) 2020-11-30
BR112020020804A2 (pt) 2021-01-12
IL277725B1 (en) 2023-10-01
IL277725B2 (en) 2024-02-01
EP3773603A4 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2021001228A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CL2018001230A1 (es) Tratamiento de osteoartritis
CO2021006672A2 (es) Moduladores de nlrp3
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
MX2019009361A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
MX2018016331A (es) Formas cristalinas de compuesto de triazolopirimidina.
MX2018003161A (es) Metodos para tratar infecciones por virus arenaviridae y coronaviridae.
MX378299B (es) Metodos para tratar infecciones por el virus de filoviridae.
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CO2017001884A2 (es) Polimorfos de selinexor
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
MX2015012736A (es) 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.
MX385138B (es) Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes.
MX2018010993A (es) Derivados de icariina e icaritina.
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112016017317A8 (pt) composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
CO2017010530A2 (es) Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv